Ankur Bindal
Psychiatry · Chula Vista, CANPI 1588820880
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.0%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Teva Pharmaceuticals USA, Inc. accounts for 64.3% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2019 at $10,262 and has fallen 96.5% since, to $358 in 2025. Among psychiatry clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 283 payments — averaging $94.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$17K
- Neuronetics, Inc.$6K
- Alkermes, Inc.$640
- Janssen Scientific Affairs, LLC$400
- Neurocrine Biosciences, Inc.$349
- Sunovion Pharmaceuticals Inc.$346
- plus $2K from 16 others
What the payments were for
- Consulting fees$2,80010%
- Speaking & faculty fees$15,74559%
- Travel & lodging$5612%
- Food & beverage$7,48128%
- Education$980%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 66 | $17,161 |
| Neuronetics, Inc. | 48 | $5,806 |
| Alkermes, Inc. | 33 | $640 |
| Janssen Scientific Affairs, LLC | 2 | $400 |
| Neurocrine Biosciences, Inc. | 16 | $349 |
| Sunovion Pharmaceuticals Inc. | 23 | $346 |
| Supernus Pharmaceuticals, Inc. | 17 | $308 |
| Vanda Pharmaceuticals Inc. | 12 | $264 |
| Lundbeck LLC | 12 | $255 |
| AbbVie(2 entities) | 11 | $212 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 11 | $187 |
| Otsuka America Pharmaceutical, Inc. | 8 | $163 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $149 |
| Johnson & Johnson | 5 | $116 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $89 |
| Noven Therapeutics, LLC | 3 | $64 |
| Jazz Pharmaceuticals Inc. | 4 | $58 |
| Avanir Pharmaceuticals, Inc. | 2 | $33 |
| Eisai Inc. | 2 | $28 |
| Bausch Health US, LLC | 1 | $23 |
| Livanova USA, Inc. | 1 | $18 |
| Almatica Pharma LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AUSTEDO$16,140
- NEUROSTAR TMS THERAPY$2,733
- NEUROSTAR TMS THERAPY SYSTEM$1,857
- SPRAVATO$400
How this compares
$26,686 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aripiprazole | 58 | $5,263 |
| Lurasidone Hcl | 11 | $5,083 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 38 | $3,641 |
| Bupropion XlBupropion Hcl | 103 | $2,336 |
| Quetiapine Fumarate | 72 | $1,396 |
| Buspirone Hcl | 101 | $1,231 |
| Duloxetine Hcl | 67 | $1,181 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 67 | $947 |
| Trazodone Hcl | 88 | $581 |
| Fluoxetine Hcl | 52 | $437 |
| Sertraline Hcl | 37 | $428 |
| Hydroxyzine Pamoate | 44 | $331 |
| Escitalopram Oxalate | 58 | $306 |
| Lamotrigine | 28 | $185 |
| Gabapentin | 18 | $150 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Almatica Pharma LLCSertraline Hcl | $17 | $42837 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Chula Vista
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
- Jonathan MeyerSan Diego$2.3M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
- Salima BrillmanSunnyvale$1.4M
- Bibi DasStanford$1.4M
- Konstantinos TripodisBurbank$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.